EASL 2026

DURHAM, N.C. and BEIJING, China, May 27, 2026 Brii Biosciences Limited (Brii Bio) has presented new late-breaking clinical and...

FOSTER CITY, Calif., May 28, 2026 Gilead Sciences announced new interim findings from the ongoing Phase 3 ASSURE study...

DURHAM, N.C., May 27, 2026 Precision BioSciences announced new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV,...